Sunovion Must Regroup After Setback With Dasotraline In ADHD
Sunovion must find a new path forward for its dasotraline in attention deficit/hyperactivity disorder (ADHD), following a complete response letter from the US FDA.
You may also be interested in...
The first of two Phase III trials of Supernus’ ADHD candidate has hit its endpoints in adolescents. The second is due to report in early 2019, setting the stage for regulatory filings.
Sunovion is pressing ahead with plans for an FDA filing for its ADHD drug dasotraline in adult and children patients despite ongoing uncertainty over the drug's efficacy in the older grouping.
Sumitomo Dainippon unit pays a 123% premium to acquire Cynapsus and its Phase III Parkinson's drug APL-130277, with at least one analyst speculating it paid a high price in order to avoid a bidding war.